Unbound MEDLINE

Efficacy and tolerability of candesartan cilexetil/hydrochlorothiazide and amlodipine in patients with poorly controlled mild-to-moderate essential hypertension. Journal of the renin-angiotensin-aldosterone system : JRAAS [J Renin Angiotensin Aldosterone Syst] Journal article

 
TitleEfficacy and tolerability of candesartan cilexetil/hydrochlorothiazide and amlodipine in patients with poorly controlled mild-to-moderate essential hypertension.
Author(s)Fogari R, Mugellini A, Derosa G, CANDIA (CANdesartan and DIuretic vs. Amlodipine in hypertensive patients) Study Group 
InstitutionDepartment of Internal Medicine and Therapeutics, Centro per l'Ipertensione e la Fisiopatologia Cardiovascolare, University of Pavia, Pavia. r.fogari@unipv.it
SourceJ Renin Angiotensin Aldosterone Syst 2007 Sep; 8(3):139-44.
MeSHAdult
Aged
Aged, 80 and over
Amlodipine
Angiotensin II Type 1 Receptor Blockers
Benzimidazoles
Biphenyl Compounds
Calcium Channel Blockers
Diuretics
Double-Blind Method
Drug Therapy, Combination
Edema
Female
Humans
Hydrochlorothiazide
Hypertension
Male
Middle Aged
Severity of Illness Index
Tetrazoles
Treatment Outcome
AbstractThe antihypertensive efficacy and tolerability of combination therapy with candesartan cilexetil, 16 mg plus hydrochlorothiazide (CC/HCTZ), 12.5 mg was compared with that of amlodipine, in a multicentre, double-blind, randomised, parallel-group study in patients with mild-to-moderate essential hypertension inadequately controlled by monotherapy. After a two week run-in period on existing therapy, patients with a sitting diastolic blood pressure (DBP) of 90-110 mmHg and a sitting systolic blood pressure (SBP) <or= 180 mmHg were switched to either CC/HCTZ (n=101) or amlodipine (n=102), once-daily by mouth. After eight weeks of treatment, both regimens reduced mean trough blood pressure (BP) by a similar amount: mean sitting SBP/DBP reductions were -15.4/-11.9 mmHg for CC/HCTZ, and -15.7/-12.0 mmHg for amlodipine (group differences, p=0.835/0.963). The BP of 84.2% of patients on CC/HCTZ and 84.5% on amlodipine was controlled (sitting DBP < 90 mmHg and sitting SBP < 140 mmHg) (p=1.00). Six (5.9%) patients on CC/HCTZ and 18 (17.6%) on amlodipine discontinued treatment, including one (1%) and 13 (12.7%) owing to adverse events (p<0.001). The most common adverse event was peripheral oedema, which occurred in two patients on CC/HCTZ and 19 on amlodipine. In conclusion, CC/HCTZ and amlodipine were equally effective in reducing BP in hypertensive patients not controlled by monotherapy, but CC/HCTZ was much better tolerated. Tolerance is an important clinical consideration in the chronic treatment of an asymptomatic disease.
Languageeng
Pub Type(s)Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
PubMed ID17907102
  
Advertise on this site.